← Compound index
COMPOUND RECORD / CP-88

CP-88Пептидомиметик CP-88

An experimental cyclic peptidomimetic. Mouse and laboratory studies examined its effects on hematopoiesis, the formation of blood cells.

Source linked

What the studies found

Animal research · 2024

Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation

Study of multiple preparations

Intact-mouse spleen colony formation
Control 14.5±1.6 colonies per 100,000 cells; CP-88 injected 19.9±1.3, oral 19.3±1.3; both marked p<0.05 versus control.
Stemokin in the same table
14.7±0.7 injected and 14.3±1.8 oral; neither carries a significance mark.

Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.

Study notes · methods, sources and limitations

Participants or model Source-specific experimental population

Important limitations

  • Independent replication and full risk-of-bias appraisal remain unresolved. No personalized treatment or safety conclusion follows from this record.
  • No CP-88-versus-Stemokin significance is established by separate control tests. Table 2 footnotes and Table 3 marker/header labels need clarification. Colony formation does not establish long-term stem-cell self-renewal or human benefit.

International Journal of Molecular Sciences 25(24):13385 · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About CP-88

Names in this research collection

CP88

Research background

Experimental cyclic peptidomimetic cyclo-{E(I)-E(W)}Na studied in mouse and laboratory hematopoietic assays. Human efficacy and safety are not established here.

Conference sources and research collaborators ↗

Compound class
Peptide / preparation research
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

See preparation-specific records; human benefit not established here

Study methods

Source-specific designs and limitations below

Independent replication

Related reports are not automatically independent evidence

Source access

Linked publications; access and review scope shown per record

Safety evidence

Clinical safety, product equivalence and interactions not established by this collection

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original paper reports colony formation. The significance footnotes in Table 2 and marker labels in Table 3 are unclear. Independent replication, long-term cell repopulation and human pharmacokinetics remain open questions.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2013 · EP2046778B1 · Cyclic glutamyl-tryptophan scaffold patentPlatform context · A tested cyclic compound reportedly increased antibody titers by 74%

Reported findings

One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.

Protein-antigen response
A tested cyclic compound reportedly increased antibody titers by 74%A model-antigen experiment; not autoimmune clinical efficacy or a verified AWE18/CP-88 result
Oral activity comparison
Some cyclic analogues retained oral analgesic activity where comparator peptides did notDifferent neuropeptide constructs; not evidence that every cyclic immune peptide is orally effective
All reported results, comparisons and limitations →

Platform context. The family concerns cyclic piperazine-based immunomodulatory compounds related to the chemistry discussed for CP-88 and AWE18.

The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.

Publication
EP2046778B1 ↗ · 2013-12-04
Earliest priority / filing
2006-08-04 / 2007-08-01
Original applicant / assignee
Manus Pharmaceuticals Canada Ltd
Indexed status
Active · checked 2026-11-06
Patent family
38996830 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Multifunctional bioactive compounds

Inventors: Vladislav I. Deigin.

EP2046778B1 · US8637521B2 · JP5357022B2 · CN101511823B · AU2007280995C1 · BRPI0714616A2 · CA2659875C · EA018548B1 · MX2009001351A · WO2008014613A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2013

Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1

One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.

Study notes and original source
2013Patent / reported experimentsFull text available

Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Vladislav I. Deigin · EP2046778B1 · patent family 38996830

One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.

Results and tables

Reported patent results

Reported findings

One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.

Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.

Population or model Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.

Results · Examples covering platform immune response and oral neuropeptide comparisons; exact candidate mapping unresolved.
MeasureResultComparison, timing and statistics
Protein-antigen responseA tested cyclic compound reportedly increased antibody titers by 74%A model-antigen experiment; not autoimmune clinical efficacy or a verified AWE18/CP-88 result
Oral activity comparisonSome cyclic analogues retained oral analgesic activity where comparator peptides did notDifferent neuropeptide constructs; not evidence that every cyclic immune peptide is orally effective

Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.
  • Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2024

Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation

Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.

Study notes and original source
2024Animal / experimentalFull text available

Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation

Defined synthetic peptide / analogue

Vladislav Deigin, Yulia Vinogradova, Dmitriy Vinogradov, Natalia Linkova, Anastasiia Dyatlova, Dmitrii Medvedev, Alexander Krasichkov, Victoria Polyakova · International Journal of Molecular Sciences 25(24):13385

Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.

Results and tables

Reported findings and study design

Population or model Source-specific experimental population

Results · Original full-text XML; Table 1 and reporting limitations in Tables 2–3
MeasureResultComparison, timing and statistics
Intact-mouse spleen colony formationControl 14.5±1.6 colonies per 100,000 cells; CP-88 injected 19.9±1.3, oral 19.3±1.3; both marked p<0.05 versus control.
Stemokin in the same table14.7±0.7 injected and 14.3±1.8 oral; neither carries a significance mark.

No CP-88-versus-Stemokin significance is established by separate control tests. Table 2 footnotes and Table 3 marker/header labels need clarification. Colony formation does not establish long-term stem-cell self-renewal or human benefit.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Source-specific experimental population
Source reviewed
Original full text retrieved from Europe PMC; experimental scope and interpretation checked. Supplementary methods and independent replication remain review targets.
Study limitations
  • Independent replication and full risk-of-bias appraisal remain unresolved.
  • No personalized treatment or safety conclusion follows from this record.

Reviewed 2026-11-06.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗